How family offices should back healthcare

The four pillars we apply

Clinical robustness.

Health economic impact.

Regulatory readiness.

Pathway integration.

These are the four pillars we apply at Nordgulf Alliance when assessing healthcare investments. If a technology cannot demonstrate all four in real healthcare systems, it simply will not scale, no matter how impressive the science looks on paper.

Yesterday in Dubai at the Global Family Office Investment Summit, this was the core message I shared on stage when asked a simple question: how do you identify healthcare investments that actually scale?

The reality is that failure in healthtech is rarely a science problem. It is an adoption problem.

A company can achieve FDA or CE approval, show promising pilot results, and still spend years struggling to integrate into health systems or secure reimbursement. That gap between innovation and adoption is where many promising technologies stall.

Family offices are uniquely positioned to help close that gap. They can deploy patient capital across longer timelines, stage investment against regulatory and adoption milestones, and open doors that might otherwise take years to access.

In the Gulf especially, the combination of capital, credibility, and local access changes the execution equation entirely.

Grateful to have shared the stage with such a strong group of panellists, and thank you to the organisers for delivering a first class event.

The real value, as always, is turning these conversations into deployed solutions that actually reach patients. Looking forward to continuing those discussions on day two.

Most family offices are doing it wrong

Family offices are allocating to healthcare AI.

Most are doing it wrong.

The pattern I see: capital flowing to “AI-enabled” platforms with impressive demos but zero clinical validation, no regulatory pathway, and founders who’ve never stood at a bedside.

What separates healthcare AI that scales from healthcare AI that stalls? Clinical-grade evidence, regulatory fluency, and operators who understand that in medicine, “move fast and break things” breaks patients.

I’m speaking on this at the Global Family Office Investment Summit in Dubai this week.

Honoured to join as a VIP Speaker for their 10th anniversary edition.

Ten years of GFOIS. There’s a reason the room keeps coming back.

The clock, not the science

I’ve sat across from founders building healthcare products I’d happily proudly put in front of my own patients. And watched the same thing sink them.

Not the science.

Not patient need.

Not clinician backing.

But it’s the clock.

Their investors needed an exit in five years. Sometimes three.

Healthcare has never once kept to that timetable.

Start with why healthtech stalls, because it’s almost never the technology. McKinsey’s own work on health systems found that 75% of executives still can’t deliver on their digital ambitions, which they read plainly as a failure to scale. The pilot works. The rollout doesn’t.

Underneath that sits a harder number. The figure most quoted in my world is fifteen to seventeen years, the rough average for new clinical evidence to reach everyday practice. Regulatory approval, procurement, retraining staff, proving outcomes, then proving them again in the next hospital.

That’s the timeline healthcare actually runs on.

Now hold a venture clock against it.

A venture fund needs its money back inside ten years, a buyout fund inside five to seven. So the company that needed a decade to embed gets pushed to exit at year four. Sold half-built. Quietly gone.

BCG sees the same gap from the capital side. Their latest family office report puts healthcare and deep tech near the top of the sectors that need long investment cycles, the patient capital that, in their words, most institutional investors simply can’t abide.

Here’s what neither report says out loud. The adoption lag and the capital clock are the same problem. The fifteen to seventeen years is exactly why the wrong money kills good healthcare technology before it ever gets the chance to work.

This is where family offices have a real edge, and it isn’t sharper diligence or better deal flow.

It’s time.

The patience to hold through the slow, unglamorous years where adoption actually happens and almost no headlines are written.

That’s the case I’m bringing to Lake Como this week for the Global Family Office Investment Summit . It’s a room that already thinks in decades, not quarters.

If you back healthcare, the science was never your real risk. Whether your capital can wait long enough to find out is.

Longevity: signal and noise

Second panel in two days at the 29th Global Family Office Investment Summit in Dubai. This time on regenerative medicine and longevity.

The longevity sector is at an inflection point. We have moved from anti-aging as a wellness category into healthspan engineering: clinically validated therapies that extend functional, disease-free years. Regenerative medicine is projected to reach $140 billion by 2034. The capital is moving.

The question is where to place it wisely.

And that requires a conversation the industry often avoids.

There is a meaningful difference between clinical grade regenerative medicine and a premium supplement with a longevity label.

One is advancing through rigorous clinical trials with peer reviewed evidence, regulatory oversight, and defined endpoints. The other is consumer marketing dressed in scientific language.

For investors, confusing the two is not just an intellectual error. It is a capital allocation mistake.

The ability to distinguish between a senolytic therapy with genuine evidence of clearing senescent cells and a nutraceutical making similar claims on a website is becoming a core competency for anyone deploying serious capital in this space.

What I advise family offices to look for is what I look for as a clinician: robust evidence, not testimonials. A regulatory strategy, not just a go to market plan. A team that understands reimbursement pathways and clinical integration as deeply as the biology. Because therapies that clear approval but cannot navigate system adoption do not scale. That is where capital goes to die.

Back healthspan over lifespan. Platforms over single molecules. The companies best positioned to capture long term value are not betting on one clinical programme. They are building technology infrastructure, whether that is AI driven target identification, automated cell manufacturing, or scalable gene delivery, that can serve multiple therapeutic applications across multiple markets. And look at where geography creates asymmetry.

The Gulf is building regulatory infrastructure specifically designed to accelerate adoption of regenerative therapies, creating real structural advantages for patient capital.

The next decade of regenerative medicine will be shaped not only by the science, which is accelerating, but by who can distinguish signal from noise in how that science is funded, regulated, and delivered.

Grateful to organisers for convening such a powerful community for the Summit’s 10 year anniversary.

What it means

The advice is consistent across all four pieces: back clinical evidence, a regulatory plan and a team that understands adoption, and give it the time healthcare actually needs. That is where patient capital has a real edge.